If you enjoy this content, please share it with a colleague
Bay Labs announced that new data on the company’s first-of-its-kind deep learning investigational guidance software will be presented at the upcoming American Society of Echocardiography (ASE) 30th Annual Scientific Sessions, June 21-25 in Portland, Ore.
Artificial intelligence (AI) company Bay Labs announced the presentation of two studies assessing performance of the company’s deep learning software for cardiovascular imaging. The first evaluated the software when used by medical professionals with no prior ultrasound experience to acquire diagnostic-quality echocardiograms, and the second evaluated the fully automated calculation of ejection fraction (EF) with accuracy and increased reproducibility. Results from these studies will be presented at the American College of Cardiology (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans.
A recent study conducted with the Minneapolis Heart Institute found that Bay Labs’ EchoMD AutoEF deep learning software has less variability in evaluating left ventricular ejection fraction (EF) than the average variability of cardiologists reported in literature. Results of the study were presented at the 2018 American Society of Echocardiography (ASE) Annual Scientific Sessions, June 22-26 in Nashville.
Cardiovascular imaging artificial intelligence (AI) company Bay Labs announced its EchoMD AutoEF software received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the fully automated clip selection and calculation of left ventricular ejection fraction (EF). EF is the single most widely used metric of cardiac function and used as the basis for many clinical decisions. The EchoMD AutoEF algorithms eliminate the need to manually select views, choose the best clips and manipulate them for quantification, an often time-consuming and highly variable process.